All In Biotech

Drug Trial Radar · NCT06144060

A Trial of Intravenous HRS-8427 in the Treatment of Adults With Complicate Urinary Tract Infection, Including Acute Pyelonephritis

A Multi-center, Randomized, Double-blind, Active Controlled, Parallel Groups, Phase II Study to Evaluate the Efficacy and Safety of Intravenous HRS-8427 in the Treatment of Adults With Complicate Urinary Tract Infection, Including Acute Pyelonephritis

Last checked: Nov 20, 2026Latest source record: Nov 22, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 126 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

126

Planned (sponsor's estimate)

Start

Dec 2023

Primary completion

Jun 2024

Study completion Jul 2024

Sponsor

Sponsor type
Industry
First posted
Nov 22, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The Purpose of this study is to evaluate the efficacy and safety of intravenous HRS -8427 in patients with complicated urinary tract infection, including acute pyelonephritis.

Conditions

  • Patients With Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP)

Interventions

  • HRS -8427Drug

    The dose and frequency of administration were adjusted according to the eGFR.

  • Imipenem and Cilastatin SodiumDrug

    The dose and frequency of administration were adjusted according to the eGFR .

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Composite Response of Microbiological Eradication and Clinical Response at Test of Cure (TOC)Time frame: Test of cure (TOC; 7 days after end of treatment [EOT], equivalent to Study Day 14 to 21)

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.